Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309169 | 0.80 | ALDH1A1 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3824845 | 0.79 | CYP2C9 (0.36) | CYP2C9CYP2C19 | |
| SCHEMBL3821920 | 0.76 | KMT2A (0.62) | LMNAALDH1A1MAPTSMN1; SMN2HPGD | |
| SCHEMBL277284 | 0.76 | CYP2C19 (0.86) | CYP2C9CYP2C19CA12CA1CA2 | |
| SCHEMBL1451262 | 0.76 | CA12 (0.57) | CYP2C9CYP2C19CA12CA1CA2 | |
| SCHEMBL489451 | 0.76 | CYP2C9 (0.62) | CYP2C9CYP2C19CA12CA1CA2 | |
| SCHEMBL4818530 | 0.75 | HPGD (0.43) | CYP1A2LMNAALDH1A1MAPTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9679507 | 0.74 | CYP2C19 (0.83) | CYP2C9CYP2C19CA12CA1CA2 | |
| SCHEMBL27723279 | 0.74 | CYP2C9 (0.61) | CYP2C9CYP2C19CA12CA1CA2 | |
| SCHEMBL1450741 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2479165-A1 | GLYCINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-07-25 | — | — | EP | claimed |
| US-20120184520-A1 | GLYCINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-07-19 | — | — | US | claimed |
| EP-1348706-B1 | SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2009-08-19 | — | — | EP | claimed |
| US-7297792-B2 | Pyrazolopyridines and pyrazolopyridazines as antidiabetics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-20 | — | — | US | claimed |
| US-20060223800-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES ADN ANTIDIABETICS | GARLAND STEPHEN | 2006-10-05 | — | — | US | claimed |
| US-7109199-B2 | Pyrazolopyridines and pyrazolopyridazines as antidiabetics | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-19 | — | — | US | claimed |
| US-20040072876-A1 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-15 | — | — | US | claimed |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-01-29 | — | — | US | claimed |
| EP-1348706-A1 | SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-10-01 | — | — | EP | claimed |
| EP-1319001-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-18 | — | — | EP | claimed |
| WO-2002024694-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM, P.L.C. (GB) | 2002-03-28 | — | — | WO | claimed |
| EP-2091951-B1 | PYRIDO[2,3-B]PYRAZINE AND [1,8]-NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2479165-B1 | GLYCINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-10-25 | — | — | EP | disclosed |
| US-8802679-B2 | Glycine compound | ASTELLAS PHARMA INC. (JP) | 2014-08-12 | — | — | US | disclosed |
| CN-102498091-B | Glycine compound | ASTELLAS PHARMA INC | 2014-03-05 | — | — | CN | disclosed |
| EP-0014402-A1 | Novel 20-0-acylmaytansinoids, process for their preparation and pharmaceutical compositions containing them | Takeda Chemical Industries, Ltd. (JP) | 1980-08-20 | — | — | EP | disclosed |
| EP-0011277-A1 | Dechloromaytansinoids, their production and use and pharmaceutical compositions containing them | Takeda Chemical Industries, Ltd. (JP) | 1980-05-28 | — | — | EP | disclosed |
| EP-0011276-A1 | Maytansinoids, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1980-05-28 | — | — | EP | disclosed |
| EP-0010735-A1 | Maytansinoids, their production and pharmaceutical compositions containing them | Takeda Chemical Industries, Ltd. (JP) | 1980-05-14 | — | — | EP | disclosed |
| EP-0004466-A1 | Demethyl maytansinoids and methods for producing them | Takeda Chemical Industries, Ltd. (JP) | 1979-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072876-A1 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | CYP17A1, CYP21A2, HSD17B1 | CYP2C9 97/4885CYP2C19 33/4885CA12 793/4885 |
| US-20120184520-A1 | GLYCINE COMPOUND | SLC5A1, AQP1, VAPB | CYP2C9 4612/4885CYP2C19 4708/4885CA12 3659/4885 |
| US-20060223800-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES ADN ANTIDIABETICS | ADK, PDXK, GPR119 | CYP2C9 163/4885CYP2C19 184/4885CA12 4738/4885 |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | PDXK, GCK, IAPP | CYP2C9 135/4885CYP2C19 151/4885CA12 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.